CY1115056T1 - Φαρμακευτικες συνθεσεις που περιεχουν φεντανυλη για ενδορινικη χορηγηση - Google Patents
Φαρμακευτικες συνθεσεις που περιεχουν φεντανυλη για ενδορινικη χορηγησηInfo
- Publication number
- CY1115056T1 CY1115056T1 CY20131101096T CY131101096T CY1115056T1 CY 1115056 T1 CY1115056 T1 CY 1115056T1 CY 20131101096 T CY20131101096 T CY 20131101096T CY 131101096 T CY131101096 T CY 131101096T CY 1115056 T1 CY1115056 T1 CY 1115056T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fentanyl
- intranasal administration
- pharmaceutically acceptable
- aqueous solution
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Αυτή η εφεύρεση προσφέρει μια σύνθεση για την ενδορινική χορήγηση φεντανύλης ή ενός φαρμακευτικώς αποδεκτού άλατος αυτής σε ένα ζώο, που περιέχει ένα υδατικό διάλυμα (i) φεντανύλης ή ενός φαρμακευτικώς αποδεκτού άλατος αυτής και (ii) μιας φαρμακευτικώς αποδεκτής πρόσθετης ουσίας που επιλέγεται από (α) μια πηκτίνη και (β) ένα πολοξαμερές και χιτοσάνη ή ένα άλας ή παράγωγο αυτής· με την προϋπόθεση ότι όταν η σύνθεση περιέχει μια πηκτίνη είναι ουσιαστικά ελεύθερη από δισθενή μεταλλικά ιόντα· και που σε σύγκριση με ένα απλό υδατικό διάλυμα φεντανύλης που χορηγείται ενδορινικά στην ίδια δόση, παρέχει μέγιστη συγκέντρωση πλάσματος φεντανύλης (Cmax) που είναι από 10 ως 80% αυτής που επιτυγχάνεται με χρήση ενός απλού υδατικού διαλύματος φεντανύλης που χορηγείται ενδορινικά σε πανομοιότυπη δόση φεντανύλης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0300531.1A GB0300531D0 (en) | 2003-01-10 | 2003-01-10 | Pharmaceutical compositions |
EP04701381.8A EP1635783B1 (en) | 2003-01-10 | 2004-01-12 | Pharmaceutical compositions comprising fentanyl for intranasal delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115056T1 true CY1115056T1 (el) | 2016-12-14 |
Family
ID=9950919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131101096T CY1115056T1 (el) | 2003-01-10 | 2013-12-04 | Φαρμακευτικες συνθεσεις που περιεχουν φεντανυλη για ενδορινικη χορηγηση |
Country Status (26)
Country | Link |
---|---|
US (5) | US20040166067A1 (el) |
EP (2) | EP1635783B1 (el) |
JP (1) | JP4827725B2 (el) |
KR (3) | KR20050103275A (el) |
CN (1) | CN100423709C (el) |
AU (1) | AU2004204381B2 (el) |
BR (1) | BRPI0406674B8 (el) |
CA (1) | CA2511974C (el) |
CY (1) | CY1115056T1 (el) |
DK (1) | DK1635783T5 (el) |
EA (1) | EA008500B1 (el) |
ES (2) | ES2432119T3 (el) |
FR (1) | FR14C0020I1 (el) |
GB (1) | GB0300531D0 (el) |
GE (1) | GEP20084340B (el) |
HK (1) | HK1088555A1 (el) |
IL (1) | IL169480A (el) |
MX (1) | MXPA05007333A (el) |
NO (1) | NO335127B1 (el) |
NZ (1) | NZ541018A (el) |
PL (1) | PL212950B1 (el) |
PT (2) | PT2436375T (el) |
SI (1) | SI1635783T1 (el) |
UA (1) | UA85050C2 (el) |
WO (1) | WO2004062561A2 (el) |
ZA (1) | ZA200505274B (el) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8017627B2 (en) * | 2000-07-31 | 2011-09-13 | Nycomed Danmark Aps | Fentanyl composition for nasal administration |
US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
GB0315632D0 (en) | 2003-07-04 | 2003-08-13 | West Pharm Serv Drug Res Ltd | Pharmaceutical formulations |
US20050129679A1 (en) | 2003-12-15 | 2005-06-16 | Nastech Pharmaceutical Company Inc. | Method for opening tight junctions |
EP2057982A1 (en) | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasal compositions |
GB2464282A (en) * | 2008-10-08 | 2010-04-14 | Archimedes Dev Ltd | A device for administering a dose of opioid analgesic |
CZ302789B6 (cs) | 2009-11-25 | 2011-11-09 | Zentiva, K. S. | Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva |
CN103339034B (zh) | 2011-02-04 | 2015-11-25 | 阿基米德开发有限公司 | 改进的容器 |
US20150018379A1 (en) | 2011-05-13 | 2015-01-15 | Euro-Celtique S.A. | Intranasal Pharmaceutical Dosage Forms Comprising Naloxone |
PL2903608T3 (pl) | 2012-10-03 | 2019-12-31 | Proponent Biotech Gmbh | Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych |
EP3041864B1 (en) | 2013-09-05 | 2021-07-21 | AB2 Bio SA | Il-18 binding protein (il-18bp) in inflammatory diseases |
US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
AU2016227644B2 (en) | 2015-03-05 | 2022-06-16 | Ab2 Bio Sa | IL-18 Binding Protein (IL-18BP) and antibodies in inflammatory diseases |
US9650338B1 (en) | 2016-07-29 | 2017-05-16 | VDM Biochemicals, Inc. | Opioid antagonist compounds and methods of making and using |
PL3568126T3 (pl) * | 2017-01-11 | 2024-03-25 | Torrent Pharmaceuticals Limited | Donosowa kompozycja tapentadolu |
WO2021014184A1 (en) * | 2019-07-19 | 2021-01-28 | Hikma Pharmaceuticals International Limited | Ready-to-administer fentanyl formulations |
US11160799B2 (en) * | 2019-10-22 | 2021-11-02 | Cessatech A/S | Pediatric combination |
EP4146174A1 (en) | 2020-05-06 | 2023-03-15 | AB2 Bio SA | Il-18 binding protein (il-18bp) in respiratory diseases |
GB202007404D0 (en) | 2020-05-19 | 2020-07-01 | Nasser Syed Muhammad Tahir | Treatment for viral respiratory infections |
EP3943097A1 (en) | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t cell therapy |
WO2023067348A1 (en) | 2021-10-21 | 2023-04-27 | Biosirius Ltd | Treatment for virally-induced pneumonia |
WO2023166206A1 (en) | 2022-03-04 | 2023-09-07 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in the treatment of vexas |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2125212A (en) | 1938-05-03 | 1938-07-26 | Vick Chemical Company | Therapeutic composition |
US2730483A (en) | 1952-08-12 | 1956-01-10 | Nepera Chemical Co Inc | Therapeutic compositions comprising neomycin, gramicidin and quaternary ammonium salt of thonzylamine |
BE623427A (el) * | 1961-10-10 | |||
US3184600A (en) | 1963-05-07 | 1965-05-18 | Potter Instrument Co Inc | Photosensitive apparatus for measuring coordinate distances |
JPS5885813A (ja) | 1981-11-17 | 1983-05-23 | Toyo Jozo Co Ltd | 吸収性良好な製剤 |
US4464378A (en) * | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4659696A (en) | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
JPS59163313A (ja) | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
US4486423A (en) * | 1983-04-21 | 1984-12-04 | Janssen Pharmaceutica Inc. | Stable fentanyl composition |
US4806341A (en) * | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
US5122127A (en) | 1985-05-01 | 1992-06-16 | University Of Utah | Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues |
HU193780B (en) | 1985-06-21 | 1987-11-30 | Richter Gedeon Vegyeszet | Process for producing 2-halogeno-6-methyl-ergol-9-ene derivatives and acid additional salts thereof |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
JPS62123112A (ja) | 1985-11-22 | 1987-06-04 | Sunstar Inc | 軟膏基剤 |
DE3601132A1 (de) | 1986-01-16 | 1987-07-23 | Christian Bannert | Verfahren zur behandlung der schleimhaut |
JPS62236862A (ja) | 1986-04-09 | 1987-10-16 | Nippon Kayaku Co Ltd | 人工粘液 |
ZA875317B (en) | 1986-08-01 | 1988-01-25 | Warner-Lambert Company | Transdermal compositions |
EP0267617B1 (en) | 1986-11-14 | 1992-06-24 | Theratech, Inc. | Penetration enhancement with binary system of cell envelope disordering compounds and lower alcohols |
US4826683A (en) | 1987-01-09 | 1989-05-02 | Bates Harry L | Decongestant |
US5200180A (en) | 1987-06-26 | 1993-04-06 | Christian Bannert | Pharmaceutical composition for the treatment of the human eye |
DE3726797A1 (de) | 1987-08-12 | 1989-02-23 | Bayer Ag | Arzneimittel fuer den bereich der mundhoehle |
US4915948A (en) | 1987-08-31 | 1990-04-10 | Warner-Lambert Company | Tablets having improved bioadhesion to mucous membranes |
US5457093A (en) | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
DE3827561C1 (el) | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
GB8900267D0 (en) | 1989-01-06 | 1989-03-08 | Riker Laboratories Inc | Narcotic analgesic formulations and apparatus containing same |
GB8904370D0 (en) | 1989-02-25 | 1989-04-12 | Cosmas Damian Ltd | Liquid delivery compositions |
JP2911496B2 (ja) | 1989-09-11 | 1999-06-23 | 帝國製薬株式会社 | 生理活性ポリペプチド含有高吸収性経膣剤 |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
GB2237510B (en) | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
NL9000634A (nl) | 1990-03-20 | 1991-10-16 | Catharina Ziekenhuis Stichting | Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding. |
US5397771A (en) | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
US5346703A (en) * | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
EP0491076A1 (en) | 1990-12-19 | 1992-06-24 | Theratech, Inc. | Penetration enhancement with multi-component system of N-aliphatic pyrrolidones with lower alcohols |
JPH0597706A (ja) | 1991-04-09 | 1993-04-20 | Chemex Block Drug Jv | アフタ性潰瘍および他の粘膜皮膚障害の処置方法 |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
DE69222295T2 (de) | 1992-05-26 | 1998-04-09 | Procter & Gamble | Pulverförmige pharmazeutische Zusammensetzung |
CA2140901A1 (en) | 1992-07-23 | 1994-02-05 | Naruhito Higo | Basal drug composition for percutaneous administration and pharmaceutical composition thereof |
AU5551394A (en) | 1992-11-09 | 1994-06-08 | Pharmetrix Corporation | Combined analgesic delivery methods for pain management |
US5507277A (en) * | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
US5756483A (en) | 1993-03-26 | 1998-05-26 | Merkus; Franciscus W. H. M. | Pharmaceutical compositions for intranasal administration of apomorphine |
GB9310412D0 (en) | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
SE9301877D0 (sv) | 1993-06-02 | 1993-06-02 | Kabi Pharmacia Ab | In situ gel for therapeutic use |
JPH09500132A (ja) | 1993-07-12 | 1997-01-07 | ヴァイラス リサーチ インスティチュート | ヒドロゲルマイクロカプセル化ワクチン |
US5422116A (en) | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
GB9406171D0 (en) * | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
AU685262B2 (en) | 1994-03-30 | 1998-01-15 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
AU2266995A (en) | 1994-04-21 | 1995-11-16 | Hisamitsu Pharmaceutical Co., Inc. | Percutaneously administrable base composition and percutaneously administrable drug composition prepared therefrom |
DE69523301T2 (de) * | 1994-05-13 | 2002-07-04 | Aradigm Corp | Ein narkotikum enthaltende aerosolformulierung |
GB9414966D0 (en) | 1994-07-26 | 1994-09-14 | Danbiosyst Uk | Pharmaceutical compositions for the nasal administration of antiviral agents |
FR2733420B1 (fr) | 1995-04-28 | 1997-06-27 | Sep Tarral | Preparations pectiques utilisables comme support de medicament |
ZA964320B (en) | 1995-06-05 | 1997-01-13 | Alza Corp | Device for transdermal electrotransport delivery of fentanyl and sufentanil |
PT836511E (pt) | 1995-06-05 | 2004-08-31 | Alza Corp | Dispositivo para distribuicao de fentanilo e sufentanilo por electrotransporte percutaneo |
US6881208B1 (en) | 1995-06-05 | 2005-04-19 | Joseph B. Phipps | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil |
JP3098401B2 (ja) | 1995-07-12 | 2000-10-16 | 株式会社エルティーティー研究所 | 経鼻投与用製剤 |
DE19527411A1 (de) * | 1995-07-27 | 1997-01-30 | Ackermann & Schmitt Gmbh & Co | Kupplung |
US5840731A (en) | 1995-08-02 | 1998-11-24 | Virginia Commonwealth University | Pain-alleviating drug composition and method for alleviating pain |
EP1024833A1 (en) | 1996-07-11 | 2000-08-09 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
US6667279B1 (en) | 1996-11-13 | 2003-12-23 | Wallace, Inc. | Method and composition for forming water impermeable barrier |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
GB9707934D0 (en) | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
GB2328443B (en) | 1997-08-21 | 2001-09-05 | Reckitt & Colmann Prod Ltd | In situ formation of pharmaceutically acceptable polymeric material |
RS49982B (sr) | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
ATE303131T1 (de) | 1997-12-02 | 2005-09-15 | Archimedes Dev Ltd | Zusammensetzungen zur nasalen verabreichung |
US6090368A (en) | 1998-03-03 | 2000-07-18 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine |
US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
CA2341732C (en) | 1998-08-26 | 2008-08-19 | Teijin Limited | Powder composition for nasal administration |
SE9803239D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
GB9823246D0 (en) | 1998-10-24 | 1998-12-16 | Danbiosyst Uk | A nasal drug delivery composition |
JP2000229859A (ja) | 1999-02-12 | 2000-08-22 | Teijin Ltd | 安定なブプレノルフィン経鼻製剤 |
WO2000047203A1 (en) | 1999-02-12 | 2000-08-17 | Mqs, Inc. | Formulation and system for intra-oral delivery of pharmaceutical agents |
US6541021B1 (en) * | 1999-03-18 | 2003-04-01 | Durect Corporation | Devices and methods for pain management |
JP2001002589A (ja) | 1999-06-18 | 2001-01-09 | Teijin Ltd | 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物 |
DE60044134D1 (de) * | 1999-08-26 | 2010-05-20 | Takeda Pharmaceutical | Nasenschleimhaut haftende matrix |
JP2001089359A (ja) | 1999-09-24 | 2001-04-03 | Toko Yakuhin Kogyo Kk | 鎮痛成分の点鼻用ゲルまたはゾル製剤 |
GB9924797D0 (en) | 1999-10-20 | 1999-12-22 | West Pharm Serv Drug Res Ltd | Compound |
AR031682A1 (es) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
PT1255547E (pt) | 2000-02-08 | 2008-11-24 | Euro Celtique Sa | Composições de libertação controlada contendo agonistas e antagonistas opióides |
CA2402865A1 (en) | 2000-03-10 | 2001-09-20 | Durect Corporation | Opioid formulations |
AU2001262992A1 (en) | 2000-05-10 | 2002-02-18 | University Of Kentucky Research Foundation | System and method for intranasal administration of opioids |
US6610271B2 (en) | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
EP1296649A2 (en) | 2000-06-22 | 2003-04-02 | Pharmasol Limited | Pharmaceutical compositions comprising an opioid analgesic |
US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
US8017627B2 (en) | 2000-07-31 | 2011-09-13 | Nycomed Danmark Aps | Fentanyl composition for nasal administration |
DE10064219B9 (de) | 2000-12-22 | 2009-02-12 | Nasalis Pain Relief International Gmbh | Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung |
US6777000B2 (en) | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
GB2378383A (en) | 2001-06-06 | 2003-02-12 | Gursharan Moonga | Nasal delivery of pharmaceutical compositions in powder form |
US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
-
2003
- 2003-01-10 GB GBGB0300531.1A patent/GB0300531D0/en not_active Ceased
-
2004
- 2004-01-08 US US10/753,628 patent/US20040166067A1/en not_active Abandoned
- 2004-01-12 KR KR1020057012821A patent/KR20050103275A/ko active Search and Examination
- 2004-01-12 ES ES04701381T patent/ES2432119T3/es not_active Expired - Lifetime
- 2004-01-12 UA UAA200507799A patent/UA85050C2/ru unknown
- 2004-01-12 PT PT11185114T patent/PT2436375T/pt unknown
- 2004-01-12 DK DK04701381.8T patent/DK1635783T5/da active
- 2004-01-12 WO PCT/GB2004/000057 patent/WO2004062561A2/en active Application Filing
- 2004-01-12 JP JP2006500187A patent/JP4827725B2/ja not_active Expired - Fee Related
- 2004-01-12 EP EP04701381.8A patent/EP1635783B1/en not_active Expired - Lifetime
- 2004-01-12 PT PT47013818T patent/PT1635783E/pt unknown
- 2004-01-12 SI SI200432094T patent/SI1635783T1/sl unknown
- 2004-01-12 KR KR1020107021362A patent/KR20100118144A/ko active IP Right Grant
- 2004-01-12 EP EP11185114.3A patent/EP2436375B1/en not_active Expired - Lifetime
- 2004-01-12 NZ NZ541018A patent/NZ541018A/en not_active IP Right Cessation
- 2004-01-12 CN CNB200480002000XA patent/CN100423709C/zh not_active Expired - Lifetime
- 2004-01-12 KR KR1020097010700A patent/KR101012148B1/ko active IP Right Grant
- 2004-01-12 CA CA2511974A patent/CA2511974C/en not_active Expired - Fee Related
- 2004-01-12 GE GEAP20048931A patent/GEP20084340B/en unknown
- 2004-01-12 BR BRPI0406674A patent/BRPI0406674B8/pt active IP Right Grant
- 2004-01-12 MX MXPA05007333A patent/MXPA05007333A/es active IP Right Grant
- 2004-01-12 EA EA200501105A patent/EA008500B1/ru not_active IP Right Cessation
- 2004-01-12 ES ES11185114T patent/ES2721899T3/es not_active Expired - Lifetime
- 2004-01-12 AU AU2004204381A patent/AU2004204381B2/en active Active
- 2004-01-12 PL PL377823A patent/PL212950B1/pl unknown
-
2005
- 2005-06-24 NO NO20053119A patent/NO335127B1/no not_active IP Right Cessation
- 2005-06-29 IL IL169480A patent/IL169480A/en active IP Right Grant
- 2005-06-29 ZA ZA2005/05274A patent/ZA200505274B/en unknown
-
2006
- 2006-09-20 HK HK06110437.4A patent/HK1088555A1/xx not_active IP Right Cessation
-
2008
- 2008-03-13 US US12/047,388 patent/US8216604B2/en active Active
-
2012
- 2012-07-03 US US13/541,314 patent/US8889176B2/en not_active Expired - Fee Related
- 2012-07-03 US US13/541,325 patent/US9078814B2/en not_active Expired - Fee Related
-
2013
- 2013-12-04 CY CY20131101096T patent/CY1115056T1/el unknown
-
2014
- 2014-03-13 FR FR14C0020C patent/FR14C0020I1/fr active Active
-
2015
- 2015-06-23 US US14/747,289 patent/US9814705B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115056T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν φεντανυλη για ενδορινικη χορηγηση | |
CY1120994T1 (el) | Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων | |
CY1105000T1 (el) | Χρηση της σπινοσαδης ή μιας συνθεσεως περιεχουσης σπινοσαδη | |
CY1105362T1 (el) | Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα | |
CY1119481T1 (el) | Εισπνευσιμη επινεφρινη | |
CY1117470T1 (el) | Στερεα δοσολογικα σκευασματα με βελτιωμενη ενδοστοματικη προσροφηση | |
CY1116464T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
CY1106522T1 (el) | Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο | |
IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
CY1115289T1 (el) | Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη | |
CY1105608T1 (el) | Φαρμακευτικες συνθεσεις παραγωγου του λευκοχρυσου | |
CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
CY1107384T1 (el) | Ταχεως διασπειρομενες μορφες δοσομετρησεως ανευ ζελατινης | |
CY1110395T1 (el) | Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης | |
HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
CY1112499T1 (el) | Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων | |
CY1106704T1 (el) | Αλογονουχος συνθεση, η μεθοδος παρασκευης της και οι χρησεις της | |
SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
CY1111698T1 (el) | Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης | |
EA200500985A1 (ru) | Твердая лекарственная форма для перорального применения | |
CY1112173T1 (el) | Η χρηση της cilobradine ή των φαρμακευτικα αποδεκτων αλατων αυτης για την θεραπεια ή την προληψη της καρδιακης ανεπαρκειας | |
DK1458393T3 (da) | Substituerede diketopiperaziner som oxytocinantagonister | |
CY1110415T1 (el) | Πρωτοτυπα παραγωγα τετραϋδροκαρβαζολιου με βελτιωμενη βιολογικη δραση και βελτιωμενη διαλυτοτητα, ως συνδετες για υποδοχεις συζευγμενους με πρωτεϊνη g (gpcrs) |